Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Samanta, R.
Shoukrey, K.
and
Griffiths, R.
2011.
Rheumatoid arthritis and anaesthesia.
Anaesthesia,
Vol. 66,
Issue. 12,
p.
1146.
Kobelt, Gisela
Lekander, Ingrid
Lang, Andrea
Raffeiner, Bernd
Botsios, Costantino
and
Geborek, Pierre
2011.
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
International Journal of Technology Assessment in Health Care,
Vol. 27,
Issue. 3,
p.
193.
Nguyen, Christine M.
Bounthavong, Mark
Mendes, Margaret A.S.
Christopher, Melissa L.D.
Tran, Josephine N.
Kazerooni, Rashid
and
Morreale, Anthony P.
2012.
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis.
PharmacoEconomics,
Vol. 30,
Issue. 7,
p.
575.
Tsao, Nicole W.
Bansback, Nick J.
Shojania, Kam
and
Marra, Carlo A.
2012.
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Best Practice & Research Clinical Rheumatology,
Vol. 26,
Issue. 5,
p.
659.
Lekander, Ingrid
Borgström, Fredrik
Lysholm, Jörgen
van Vollenhoven, Ronald F.
Lindblad, Staffan
Geborek, Pierre
and
Kobelt, Gisela
2013.
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.
The European Journal of Health Economics,
Vol. 14,
Issue. 6,
p.
863.
Linde, Louise
Sørensen, Jan
Østergaard, Mikkel
and
Hetland, Merete Lund
2013.
Gain in Quality-adjusted Life-years in Patients with Rheumatoid Arthritis During 1 Year of Biological Therapy: A Prospective Study in Clinical Practice.
The Journal of Rheumatology,
Vol. 40,
Issue. 9,
p.
1479.
Lekander, Ingrid
Kobelt, Gisela
Svarvar, Patrick
Ljung, Tryggve
van Vollenhoven, Ronald
and
Borgström, Fredrik
2013.
The Comparison of Trial Data–Based and Registry Data–Based Cost-Effectiveness of Infliximab Treatment for Rheumatoid Arthritis in Sweden Using a Modeling Approach.
Value in Health,
Vol. 16,
Issue. 2,
p.
251.
Soini, Erkki J
Leussu, Miina
and
Hallinen, Taru
2013.
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
SpringerPlus,
Vol. 2,
Issue. 1,
van Haalen, H. G. M.
Severens, J. L.
Tran-Duy, A.
and
Boonen, A.
2014.
How to Select the Right Cost-Effectiveness Model?.
PharmacoEconomics,
Vol. 32,
Issue. 5,
p.
429.
Heather, Eleanor M.
Payne, Katherine
Harrison, Mark
and
Symmons, Deborah P. M.
2014.
Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models.
PharmacoEconomics,
Vol. 32,
Issue. 2,
p.
109.
Tosh, Jonathan
Stevenson, Matt
and
Akehurst, Ron
2014.
Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review.
Current Rheumatology Reports,
Vol. 16,
Issue. 10,
Kobelt, Gisela
2014.
Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved.
Value in Health,
Vol. 17,
Issue. 5,
p.
537.
Scholz, Stefan
and
Mittendorf, Thomas
2014.
Modeling rheumatoid arthritis using different techniques - a review of model construction and results.
Health Economics Review,
Vol. 4,
Issue. 1,
Kvamme, Maria K.
Lie, Elisabeth
Uhlig, Till
Moger, Tron A.
Kvien, Tore K.
and
Kristiansen, Ivar S.
2015.
Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Rheumatology,
Vol. 54,
Issue. 7,
p.
1226.
Krol, Marieke
and
Brouwer, Werner
2015.
Unpaid work in health economic evaluations.
Social Science & Medicine,
Vol. 144,
Issue. ,
p.
127.
Joensuu, Jaana T.
Huoponen, Saara
Aaltonen, Kalle J.
Konttinen, Yrjö T.
Nordström, Dan
Blom, Marja
and
Coles, Jonathan A
2015.
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review.
PLOS ONE,
Vol. 10,
Issue. 3,
p.
e0119683.
Krol, Marieke
Papenburg, Jocé
and
van Exel, Job
2015.
Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies.
PharmacoEconomics,
Vol. 33,
Issue. 2,
p.
123.
Joensuu, Jaana T.
Aaltonen, Kalle J.
Aronen, Pasi
Sokka, Tuulikki
Puolakka, Kari
Tuompo, Riitta
Korpela, Markku
Vasala, Mikko
Ilva, Kirsti
Nordström, Dan
and
Blom, Marja
2016.
Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Rheumatology,
Vol. 55,
Issue. 10,
p.
1803.
Stevenson, Matt
Archer, Rachel
Tosh, Jon
Simpson, Emma
Everson-Hock, Emma
Stevens, John
Hernandez-Alava, Monica
Paisley, Suzy
Dickinson, Kath
Scott, David
Young, Adam
and
Wailoo, Allan
2016.
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Health Technology Assessment,
Vol. 20,
Issue. 35,
p.
1.
Alemao, Evo
Al, Maiwenn J.
Boonen, Annelies A.
Stevenson, Matthew D.
Verstappen, Suzanne M. M.
Michaud, Kaleb
Weinblatt, Michael E.
Rutten-van Mölken, Maureen P. M. H.
and
Nurmohamed, Michael
2018.
Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.
PLOS ONE,
Vol. 13,
Issue. 10,
p.
e0205013.